1. Home
  2. MIST vs CNTB Comparison

MIST vs CNTB Comparison

Compare MIST & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

HOLD

Current Price

$0.37

Market Cap

95.3M

Sector

Health Care

ML Signal

HOLD

Logo Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

HOLD

Current Price

$0.59

Market Cap

140.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIST
CNTB
Founded
2003
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.3M
140.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
MIST
CNTB
Price
$0.37
$0.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
7
Target Price
$3.86
★ $5.71
AVG Volume (30 Days)
★ 2.0M
569.3K
Earning Date
11-13-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $64,000.00
Revenue This Year
$215.89
$7,473.67
Revenue Next Year
$157.01
$240.46
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.36
$0.55
52 Week High
$3.06
$3.82

Technical Indicators

Market Signals
Indicator
MIST
CNTB
Relative Strength Index (RSI) 29.89 34.22
Support Level N/A N/A
Resistance Level $0.84 $2.62
Average True Range (ATR) 0.08 0.07
MACD -0.03 0.01
Stochastic Oscillator 2.26 16.72

Price Performance

Historical Comparison
MIST
CNTB

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Share on Social Networks: